Merck & Co: stocks, financial statements

Disable ads for free
Dividends News

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

  • MRK Ticker
  • NYSE Exchange
  • 69,000 Employees
17 rated
  • $80.06, $-0.08 (-0.10%) Previous Close
  • 5,721,491 Previous Volume
  • $65.25 / $92.64 52 week low / high
  • -13.49% Percent off 52 week high
  • 2020-11-25 Updated
  • 3.04% Dividend Yield (trailing)
  • 3.24% Dividend Yield (forward)
  • 2,528,425,961 Public float
  • 2,530,030,000 Outstanding shares
  • 17.62 P/E
  • 202.76 B Market Cap
Disable ads for free

Financial statements — Merck & Co

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
19 ← 15 2019 2018 2017 2016 2015
Total Revenue
47B 42B 40B 39B 39B
Cost Of Revenue
13B 13B 13B 13B 15B
Gross Profit
34B 29B 27B 26B 24B
Research and Development
8.9B 9.5B 9.6B 6B 6.6B
Selling General and Admin
11B 10B 9.8B 9.7B 10B
Operating Expense
32B 33B 32B 29B 31B
Operating Income
13B 9.8B 8B 10B 7.4B
Other Income Expense Net
-1.8B -1.1B -1.5B -5.8B -2B
13B 9.8B 8B 10B 7.4B
Interest Income
890M 770M 750M 690M 670M
Pretax Income
11B 8.7B 6.5B 4.7B 5.4B
Income Tax
1.7B 2.5B 4.1B 720M 940M
Minority Interest
-66M -27M 24M 21M 17M
Net Income
9.8B 6.2B 2.4B 3.9B 4.4B
Net Income Basic
9.8B 6.2B 2.4B 3.9B 4.4B
19 ← 15 2019 2018 2017 2016 2015
Current cash
9.7B 8B 6.1B 6.5B 8.5B
Short term investments
770M 900M 2.4B 7.8B 4.9B
6.8B 7.1B 6.9B 7B 6.5B
6B 5.4B 5.1B 4.9B 4.7B
Other current assets
4.3B 4.5B 4.3B 4.4B 5.1B
Current assets
27B 26B 25B 31B 30B
Long term investments
2.2B 6.9B 13B 12B 14B
Property plant equipment
16B 13B 12B 12B 13B
19B 18B 18B 18B 18B
Intangible assets
14B 11B 14B 17B 23B
Other assets
4.2B 6.3B 4.7B 4.4B 4.4B
Total assets
84B 83B 88B 95B 100B
Accounts payable
3.7B 3.3B 3.1B 2.8B 2.5B
Current long term debt
Other current liabilities
14B 12B 12B 12B 13B
Total current liabilities
22B 22B 19B 17B 19B
Long term debt
24B 20B 21B 24B 24B
Other liabilities
7.8B 9.3B 8.4B 5.6B 5.4B
Minority Interest
-66M -27M 24M 21M 17M
Total Liabilities
58B 56B 53B 55B 57B
Common stock
2.5B 2.6B 2.7B 2.7B 2.8B
Retained earning
47B 43B 41B 44B 45B
Treasury stock
1.7M 1.6M 1.3M 1.3M 1.5M
Capital surplus
40B 39B 40B 40B 40B
Shareholder equity
26B 27B 34B 40B 45B
Net tangible assets
-69B -60B -53B -47B -43B
19 ← 15 2019 2018 2017 2016 2015
Net Income
9.8B 6.2B 2.4B 3.9B 4.4B
3.7B 4.5B 4.6B 5.4B 6.4B
Changes in receivables
290M -200M 140M -500M
Changes in inventories
-510M -910M -150M 210M 810M
Cash change
2B 1.9B -420M -2B 1.1B
Cash flow
13B 11B 6.4B 10B 12B
Capital expenditures
-3.5B -2.6B -1.9B -1.6B -1.3B
5.4B 7.3B 4.9B -1.3B 3.7B
Investing activity other
Total investing cash flows
-2.6B 4.3B 2.7B -3.2B -4.8B
Dividends paid
-5.7B -5.2B -5.2B -5.1B -5.1B
Net borrowings
1.2B 840M -1.1B -1.3B 3.5B
Other financing cash flows
5M -330M -200M -120M 56M
Cash flow financing
-8.9B -13B -10B -9B -5.3B
Exchange rate effect
17M -210M 460M -130M -1.3B
Disable ads for free
Disable ads for free